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Abstract We have studied the effects of TNF-a on the mRNAs 
coding for the peroxisome proliferator activated receptor a 
(PPAR-a), and for catalase (Cat), acyl-CoA oxidase (AOX), 
multifunctional enzyme (PH), and P-actin in rat liver. Total 
RNA was isolated from livers of male SD-rats 16 h after 
administration of a single dose of 25 u.g TNF-a and mRNAs 
were analyzed by a novel dot blot RNase protection assay. The 
mRNAs for P P A R - a and for Cat, AOX and P H were 
significantly reduced by TNF-treatment. In addition, the level 
of PPAR-a protein was also decreased after TNF. In contrast, 
the mRNA for P-actin was markedly increased implying that the 
effect of TNF on PPAR-a and the peroxisomal mRNAs is highly 
selective. This effect may have important implications in 
perturbation of the lipid metabolism induced by TNF-a. 
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1. Introduction 
Tumor necrosis factor a (TNF) is a potent cytokine with a 
wide range of biological activities [1-5]. One of its remarkable 
effects is the induction of severe hyperlipidemia by the stim-
ulation of hepatic lipogenesis [6,7], the suppression of lipopro-
tein lipase and elevated rate of lipolysis in adipocytes [8,9] as 
well as by the liberation of fatty acids, among them arachi-
donic acid, from cell membranes by the activation of phos-
pholipase A2 [10,11]. Peroxisomes play a key role in lipid 
metabolism and especially in the degradation of polyunsatu-
rated and very long-chain fatty acids by their P-oxidation 
system [12,13]. The genes encoding peroxisomal P-oxidation 
enzymes are regulated by nuclear receptors commonly re-
ferred to as peroxisome proliferator activated receptors 
(PPARs) which, after ligand activation bind to response ele-
ments in the promoter regions of peroxisomal P-oxidation 
genes thus acting as transcription factors [14-16]. 
In the rat liver, P P A R - a is highly expressed [17] and long 
chain fatty acids and arachidonic acid have been shown to 
serve as ligands activating P P A R - a in cultured cells [15,18]. 
Thus, the T N F mediated hyperlipidemia with increased re-
lease of activators of P P A R - a such as arachidonic acid should 
be expected to induce the transcription of peroxisomal P-ox-
idation enzymes in the liver. In a recent study however, we 
found that the activity of the peroxisomal P-oxidation enzyme 
acyl-CoA oxidase (AOX) was reduced and the corresponding 
protein levels of A O X and multifunctional enzyme (PH) were 
significantly decreased in rat liver 16 h after a single dose of 
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T N F [19]. This observation raised the question whether T N F 
also affected the P P A R - a in rat liver. The present study was 
designed to answer this question by investigating the in vivo 
effects of T N F on the m R N A s encoding peroxisomal proteins 
and especially to assess the role of P P A R - a in the TNF-medi-
ated downregulation of peroxisomal P-oxidation. 
2. Material and methods 
2.1. Animals 
Male Spraque-Dawley rats (200 g) were kept under standardized 
conditions (22°C, 12 h 7.00 h/19.00 h light/dark cycle) and were pro-
vided with chow and tap water ad libitum. They were injected via the 
tail vein with 25 ug of human recombinant TNF in 0.5 ml 0.9% saline 
or saline alone in control animals. The TNF was generously provided 
by BASF/Knoll (Ludwigshafen, Germany). Sixteen hours after the 
injection the animals were sacrificed under ether anesthesia and the 
liver was removed and quickly frozen in liquid nitrogen. 
2.2. Preparation of cRNA probes, RNA-isolation and dot blot RNase 
protection assay 
cDNA fragments of rat hepatic AOX (2.0 kbp), PH (2.1 kbp), Cat 
(1.6 kbp), PPAR-a (1.6 kbp) and P-actin (0.68 kbp) were subcloned 
into the following restriction sites of either a pGEMZf (+), a pGEN-
3zf or a pBSII SK vector AOX.EcoRVIEcoRl; PH:BamHVSphI; 
Cat: HindlUIEcoRI; PPARa-.BamHVXbal. The cDNA fragment of 
PPAR-a was a generous gift of Dr. J.A. Gustafsson (Karolinska In-
stitute, Ffuddinge, Sweden). The fragment of P-actin was a gift of Dr. 
H. Hermann (German Cancer Research Center, Heidelberg, Ger-
many) which was subcloned in a pGEM3Z vector using the BglXl 
restriction enzyme. The cDNAs were transcribed to corresponding 
cRNAs and were concomitantly digoxigenin-labeled by means of a 
commercial Dig-RNA-labeling kit (Boehringer Mannheim, Germany). 
Total RNA was extracted from liver tissue by means of guanidi-
nium thiocyanate/phenol chloroform using the Roti-Quick-Kit (Carl 
Roth, Karlsruhe, Germany). RNA was quantified by spectrophotom-
etry at 260/280 nm and its integrity was assessed by denaturing 1% 
agarose gel electrophoresis (ratio of ribosomal 28S vs 18S). For the 
dot blot RNase protection assay developed recently in our laboratory 
[20] 1 JJ.1 = 1 ug each of total RNA was dotted on a nylon membrane 
('Qiabrane', Qiagen, Hilden, Germany) and crosslinked by means of 
an UV Stratalinker (Stratagene). Blots were prehybridized at 68°C for 
2 h and hybridized overnight at the same temperature with digoxige-
nin-labeled cRNA probes adjusted to a concentration of 100 ng/ml. 
After hybridization, membranes were incubated for 10 min at room 
temperature with ribonuclease A (1 ag/ml) followed by washing and 
incubation in blocking buffer (Blocking reagent, Boehringer, Mann-
heim Germany). Dig-labeled RNA hybrids were detected by chemilu-
minescence using alkaline phosphatase-labeled anti Dig Fab-frag-
ments and a chemiluminescence substrate (CDP-Star, Boehringer 
Mannheim, Germany). The signals obtained were quantified by densi-
tometry (Quantimet 500+, Leica, Germany). For statistical analysis 
Student's ?-test was used. 
2.3. Immunoblotting 
Liver was homogenized in a buffer containing 10 mM Tris-HCl, 
20 mM sodium molybdate, 1.5 mM EDTA and 0.6 M KC1, pH 8. 
For immunoblotting equal amounts of protein from liver homogenate 
were subjected to SDS-PAGE and after electrotransfer onto nitrocel-
lulose the sheets were incubated overnight with a monospecific anti-
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body to PPAR-a. The antibody was a generous gift of Dr. J.A. Gus-
tafsson, Karolinska Institute, Huddinge, Sweden. After repeated 
washing, a peroxidase-conjugated goat anti-rabbit antibody 
(1:10000, Sigma, Miinchen, Germany) was added for 1 h at room 
temperature, and the immunoreactive bands were visualized by en-
hanced chemiluminescence (ECL, Amersham International, Amer-
sham, England). 
3. Results and discussion 
The animals tolerated the injection of TNF well and did not 
develop any signs of toxicity. 
The mRNAs for the peroxisomal P-oxidation enzymes 
AOX and PH were significantly decreased 16 h after TNF-
treatment (Fig. 1). This is in line with our previously reported 
results of immunocytochemistry and western blot analysis 
which had revealed significant reduction of the corresponding 
enzyme proteins in TNF-treated animals [19]. Concomitantly, 
the mRNA for PPAR-a (Fig. 1) as well as the corresponding 
PPAR-a-protein (Fig. 2) were significantly reduced after 
TNF-treatment. Most recently, another member of the 
PPAR-family, the PPAR-y has been reported to be down-
regulated by TNF in isolated adipocytes [21]. In contrast to 
PPAR-a, however, the PPAR-y is not expressed in the liver 
[17] and its main function is supposed to be the regulation of 
adipocyte gene expression and differentiation [22]. 
The TNF-mediated reduction of PPAR-a found in the 
present study most probably contributes to the decrease of 
peroxisomal P-oxidation after TNF-treatment. Another mech-
anism for TNF-induced downregulation of peroxisomal p-ox-
idation could be related to its interaction with c-jun. TNF 
stimulates the expression of c-jun [23] and c-jun and PPAR-
a mutually inhibit each other's transactivation functions [24]. 
Thus, the two effects of TNF, the direct reduction of PPAR-a 
level and the induction of c-jun expression which would inhibit 
the PPAR-a function may have an additive effect in the di-
minuition of peroxisomal P-oxidation. Since the peroxisomal 
P-oxidation plays an important role for degradation of very 
long chain and polyunsaturated fatty acids [12,13] the dimin-
uition of the peroxisomal P-oxidation after TNF-treatment 
could contribute to the TNF-mediated hyperlipidemia. The 
biological importance of the hyperlipidemia after TNF-treat-
ment may be related to the protective effect of lipoproteins 
against endotoxin toxicity and viruses as suggested by Harris 
et al [25]. Accordingly, the downregulation of PPAR-a could 
play an important role in this response to TNF. Moreover, the 
downregulation of peroxisomal P-oxidation which is involved 
in degradation of prostaglandins [26] and leukotriens [27] 
could contribute to the intensification of inflammation-induc-
ing effects of TNF. Indeed, PPAR-a most recently has been 
discussed to play a central role in inflammation control [28]. 
In addition to the mRNAs of PPAR-a and the peroxisomal 
p-oxidation enzymes, the mRNA for catalase was also signifi-
cantly decreased 16 h after TNF-treatment (Fig. 1). This re-
sult does not correlate with the enzyme activity and protein 
level of catalase which were only slightly but insignificantly 
decreased at this time after TNF-treatment [19]. This discrep-
ancy suggests that catalase may have a longer turn-over rate 
than AOX and PH. Indeed, in livers of rats treated for 5 days 
with TNF, catalase activity was reported to be significantly 
decreased [29]. 
Surprisingly, the mRNA for P-actin was more than 100% 
increased after TNF-treatment (Fig. 1). Since the biochemical 
data do not provide any information to the cellular origin of 
P-actin mRNA, in situ hybridization experiments are now in 
progress to elucidate this. In rat liver besides the hepatocytes, 
the perisinusoidal fat-storing cells (Ito-cells, lipocytes) may be 
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Fig. 1. Dot blot RNase protection assays for mRNAs of catalase (Cat), acyl-CoA oxidase (AOX), multifunctional enzyme (PH), peroxisome 
proliferator activated receptor-a (PPAR) and B-actin. The diagram below shows the results of the densitometric analysis. Controls were set to 
100%, « = 4 animals per group. The bars represent means with S.E.M. *Significant differences to controls (P<0.05). 
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Fig. 2. Immunoblot of total liver homogenate from 4 controls and 
4 TNF-treated animals incubated with an antibody to PPAR-oe fol-
lowed by visualization with the ECL technique. Controls were set 
to 100%. The diagram shows the results of the densitometric analy-
sis. The bars represent means with S.E.M. *Significant difference to 
controls (P < 0.05). 
promising candidates since they have been reported to trans-
form to myofibroblasts after TNF-t rea tment [30]. 
The m R N A of P-actin which is considered as a stable con-
stitutive protein, has been widely used as an intrinsic control 
for normalization of different m R N A levels. Accordingly, 
T N F treatment did not alter P-actin m R N A in fibroblasts 
[31], adenocarcinoma cell lines [32,33] or adipocytes [21]. 
However, our current results of increased P-actin m R N A in 
rat liver in combination with a recent report of decreased p-
actin m R N A in microvascular endothelial cells after exposure 
to T N F [34] cast doubt on the value of P-actin as a reliable 
reference for normalization of other m R N A s under experi-
mental conditions. 
The mechanisms by which T N F downregulates the m R N A s 
for PPAR-oe and catalase remains unknown. In the last years, 
several novel proteins have been identified that interact with 
members of the TNF-receptor superfamily to initiate intra-
cellular signal transduction events [5,23,35,36]. Hitherto, how-
ever no direct link has been established between TNF-act ion 
and the regulation of peroxisomal genes. In contrast to T N F , 
a variety of peroxisome proliferating agents such as perflour-
odecanioc acid and W Y 14,643 induce the m R N A of PPAR-cc 
in rat liver and hepatoma cell lines [37]. The knowledge of 
various factors upregulating the m R N A of PPAR-oc in com-
bination with the downregulation of P P A R m R N A by T N F 
as revealed here, may be helpful for elucidation of the exact 
mechanisms involved in the regulation of P P A R - a . 
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